Cancer Cell
Volume 40, Issue 6, 13 June 2022, Pages 590-591
Journal home page for Cancer Cell

Letter
Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies

https://doi.org/10.1016/j.ccell.2022.05.007Get rights and content
Under an Elsevier user license
open archive

Cited by (0)

8

These authors contributed equally